Why Is Alignment Healthcare (ALHC) Stock Down -28.13% Today?
Key Takeaways
- ALHC shares plunged roughly 28% intraday after CMS released 2027 Medicare Advantage Star Ratings.
- The company's largest contract, the California H3815 HMO plan covering about 75% of membership, was downgraded from 4.0 stars to 3.5 stars.
- The lower rating makes the plan ineligible for certain quality bonus payments, pressuring financials for fiscal 2028.
- Multiple analysts downgraded the stock, including BofA (Neutral from Buy) and William Blair (Market Perform from Outperform).
- Alignment Healthcare says it will pursue administrative appeals and litigation challenging the ratings methodology.
- Traders are watching for further analyst actions, potential CMS appeals, and the company's upcoming earnings.
Opening Summary
Alignment Healthcare, Inc. (ALHC), a Medicare Advantage-focused health insurer serving seniors primarily in California and other select states, saw its stock tumble sharply in Friday's session after federal regulators released new quality ratings. The shares fell approximately 28.13% to around $6.26, down from the prior session's close of $8.71. The decline reflects a downgrade of the company's largest health plan contract under the Centers for Medicare & Medicaid Services (CMS) Star Ratings program, a change that directly threatens a meaningful stream of future bonus revenue and prompted a wave of sell-side downgrades.
CMS Star Ratings Downgrade Hits the Core Contract
The primary catalyst behind the sell-off is the October 8 release of CMS's 2027 Star Ratings for Medicare Advantage and Medicare Part D plans. Alignment Healthcare disclosed that its California HMO contract (H3815) is expected to receive a 3.5-star rating for 2027, down from 4.0 stars in 2026. That single contract serves roughly 75% of the company's health plan membership, making the downgrade disproportionately consequential.
Under the Medicare Advantage framework, plans rated at 4.0 stars or higher qualify for quality bonus payments that enhance reimbursement. Falling to 3.5 stars removes H3815 from that bonus-eligible tier. Alignment said the ratings change is not expected to affect revenue for fiscal 2026 or 2027, but it will impact quality bonus payments for fiscal 2028. The company expects provider risk-sharing arrangements to offset a portion of the financial hit, yet investors focused on the loss of a key revenue tailwind responded decisively.
Alignment attributed the decline primarily to higher industry cut points and weaker performance in certain triple-weighted measures across the Health Outcomes Survey and Part D. It also criticized CMS's decision to retroactively eliminate bonus calculations tied to the Health Equity Index, arguing that the current methodology no longer consistently reflects member quality, outcomes, and experience.
Analyst Downgrades Amplify Selling Pressure
The ratings news triggered a rapid reassessment on Wall Street. BofA downgraded ALHC to Neutral from Buy and slashed its price target to $9 from $25, noting that Alignment posted the weakest Star Ratings performance in its peer group, with the share of membership in 4+ star plans falling from roughly 100% to about 25%. The firm argued that losing the 5% bonus on 4-star plans reduces the company's margin for error as it continues to expand.
William Blair likewise cut its rating to Market Perform from Outperform, cautioning that third-quarter results could reveal cost-trend challenges and that the ratings overhang makes it difficult for the stock to work over the next 12 months. The combined downgrades reinforced the bearish narrative and added institutional selling pressure to an already weak open.
Market Context and Trading Activity
The move was broad-based and dramatic, with shares opening well below the prior close and trading near their lows of the day. Volume ran elevated as investors repriced the stock in response to the regulatory development, with pre-market trading already signaling a decline of more than 20%. The sell-off pushed the stock toward multi-month and 52-week lows, reflecting the market's focus on the longer-term earnings implications of the ratings change.
The decline is largely company-specific rather than a function of broad market weakness. While the managed-care and Medicare Advantage sector has faced recurring scrutiny over reimbursement and prior-authorization rules, Alignment's drop stands out because the Star Ratings outcome directly hits its single largest membership base. The divergence from peers underscores that investors are treating this as an idiosyncratic regulatory setback tied to the company's concentrated California footprint.
What Comes Next for ALHC
The near-term path for ALHC hinges on several factors. The company has said it intends to pursue administrative appeals and expects to commence litigation challenging certain Star Ratings measures and methodologies it views as inconsistent with applicable law and CMS's statutory authority. Any success on those fronts could meaningfully alter the outlook, though such processes are typically lengthy and uncertain.
Alignment also plans enterprise-wide initiatives — including enhanced member and provider engagement and expanded care-gap closure programs — aimed at returning H3815 to a 4.0-star rating in future years. With roughly half of its membership having joined within the last two years, management contends that embedded earnings growth can support its margin trajectory. Investors will be watching the company's next earnings report for updated commentary on cost trends and any revisions to guidance, as well as any further analyst rating actions following the downgrades. Risks remain, including potential litigation outcomes, continued regulatory scrutiny of Medicare Advantage, and the execution risk inherent in restoring the plan's quality rating.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently among the strongest performers in today's market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies varying by approach, timeframe, performance metrics, and the symbols they trade. Exploring this section can help traders discover automated tools aligned with their own objectives and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ALHC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 15, 2026
ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where ALHC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALHC's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ALHC as a result. In 54 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on October 02, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 252 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ALHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (6.203) is slightly higher than the industry average of (3.247). P/E Ratio (41.737) is within average values for comparable stocks, (139.958). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement